Indeed, the up-regulation of TIM-3 and CTLA-4 on T lymphocytes driven by HLA-G may be dampened by the inhibition of HLA-G/ILT2 interaction, thus increasing the re-activation of T cell responses against tumor cells. The gene discussed is HAVCR2; the disease is neoplasm.